Clinical Trials for AIM ImmunoTech

Explore 3 clinical trials worldwide

Showing 1-3 of 3 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: AIM ImmunoTech

Clinical Trials (3)

NCT05927142
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
PHASE1/PHASE2Recruiting
43 participants
Started: Jan 9, 2024 · Completed: Apr 30, 2027
1 condition3 sponsors1 location
NCT03899987
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
PHASE2Active, not recruiting
12 participants
Started: Nov 29, 2019 · Completed: Nov 29, 2026
10 conditions2 sponsors1 location
NCT03734692
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
PHASE1/PHASE2Active, not recruiting
24 participants
Started: Jan 28, 2019 · Completed: Jan 10, 2027
1 condition3 sponsors1 location